Pendopharm and Kalvista Team Up to Launch Oral HAE Treatment in Canada

Pendopharm® and Kalvista® Collaborate to Broaden Treatment in Canada

Image Credits: AInvest

Announcement

Pendopharm®, a part of Pharmascience Inc., has signed a distribution agreement with Kalvista Pharmaceuticals Inc., a leading biopharmaceutical company known for its development in oral treatments for rare diseases. The agreement gives Pendopharm® the authority to commercialize sebetralstat (investigational; oral therapy for hereditary angioedema (HAE), introduced by kalvista® in Canada) and manage regulatory approval. The financial details of the agreement are undisclosed.

Sebetralstat

Sebetralstat is the first oral medication approved for the treatment of hereditary angioedema in Canada. This treatment identifies the complex and required needs of patients suffering from HAE. This condition is a rare and life-threatening genetic disorder caused due to unaware episodes of serious swelling. This therapy is under regulatory review in various countries as a capable oral therapy for HAE.

HAE

HAE is a swelling that occurs in several parts of the body, including the feet, stomach, hands, throat, genitals, and face. Mainly, swelling in the airway may cause serious breathing problems. Most of the people with HAE have a genetic defect that leads to a deficiency in the plasma protein known as C1-inhibitor. HAE is also found in individuals having normal levels of C1-inhibitor. Genetic defects in other genes lead to angioedema.

Strategy

Addressing the requirement of treatment and a needed push to the healthcare market leads to collaboration and expansion. This partnership will fuel patient care and encourage the development of innovation in other regions. The green signal for the new therapy/treatment is a solution and relief for healthcare providers, management, and patients. Partnership in healthcare requires a mutual effort and strategy to build a stronger global foundation.

Views and Statements

Chair of the Canadian Hereditary Angioedema network, Dr. Stephen Betschel, said, “HAE can harm patients with its severe, life-threatening attacks of swelling. The new therapeutic option is most appreciated and will be an advancement in the treatment of HAE in Canada.”

Vice President and General Manager of Pendopharm®, Jad Isber, said, “The collaboration mirrors our mission to provide therapies to meet medical needs. The company is looking forward to working with healthcare providers in Canada to enable access to sebetralstat for individuals in need.”

CEO of Kalvista®, Ben Palleiko, said, “We are excited to partner with Pendopharm®, who are the experts in the Canadian healthcare landscape and are known for their excellent pharmaceutical commercialization. This makes them a suitable collaborator. The agreement is an advancement to our mission to enable access to sebetralstat globally.”